These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25163307)

  • 1. [Historical and future perspective of antithrombotic agents].
    Goto S
    Nihon Rinsho; 2014 Jul; 72(7):1193-7. PubMed ID: 25163307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized antithrombotic therapy.
    Lüscher TF; Steffel J
    Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H; Cohen M; Ezekowitz MD
    J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
    Golino P
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    ; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
    N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet agents and arterial thrombosis.
    Billett HH
    Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.
    Mega JL; Simon T
    Lancet; 2015 Jul; 386(9990):281-91. PubMed ID: 25777662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy.
    Toepfer NJ; Baylor K; Henry Y; Simmons J; Berger PB
    Urology; 2013 Oct; 82(4):773-9. PubMed ID: 23876586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy.
    Manchikanti L; Falco FJ; Benyamin RM; Caraway DL; Kaye AD; Helm S; Wargo BW; Hansen H; Parr AT; Singh V; Swicegood JR; Smith HS; Schultz DM; Malla Y; Hirsch JA
    Pain Physician; 2013 Apr; 16(2 Suppl):SE261-318. PubMed ID: 23615893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
    Davis EM; Packard KA; Knezevich JT; Campbell JA
    Pharmacotherapy; 2011 Oct; 31(10):975-1016. PubMed ID: 21950643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current evidence for monitoring platelet reactivity in acute coronary syndrome: a plea for individualized antiplatelet treatment.
    Aradi D; Sibbing D; Bonello L
    Int J Cardiol; 2013 Sep; 167(5):1794-7. PubMed ID: 23290951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.